Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Ovarian Mixed Epithelial Tumor: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Malignant Ovarian Mixed Epithelial Tumor: 2 US clinical trials tracked, none currently recruiting.
Malignant Ovarian Mixed Epithelial Tumor is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Gynecologic Oncology Group, running 1 of these trials.
Enrollment posture brief
Registry condition malignant-ovarian-mixed-epithelial-tumor
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Malignant Ovarian Mixed Epithelial Tumor has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Ovarian Mixed Epithelial Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Ovarian Mixed Epithelial Tumor is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT00262847
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Gynecologic Oncology Group
NCT00939809
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Ovarian Mixed Epithelial Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Ovarian Mixed Epithelial Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Ovarian Mixed Epithelial Tumor page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Malignant Ovarian Mixed Epithelial Tumor trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gynecologic Oncology Group sponsors the most Malignant Ovarian Mixed Epithelial Tumor trials on record, review their full trial history before evaluating a specific study. See Gynecologic Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Ovarian Mixed Epithelial Tumor condition card totals 2 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.